ArticleRSC advances2019
Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 31 citations in OpenAlex.
- The progress of biomarkers detection to lung cancer.Discover oncology · 2026Review
- Label-free immunoassay based on chemiluminescence-functionalized magnetic mesoporous nanoparticles for rapid detection of neuron-specific enolase.Mikrochimica acta · 2025Article
- Emerging Biosensing Methods to Monitor Lung Cancer Biomarkers in Biological Samples: A Comprehensive Review.Cancers · 2023Review
- Recent Progress in Biosensors for Detection of Tumor Biomarkers.Molecules (Basel, Switzerland) · 2022Review
- A Novel ssDNA Aptamer Targeting Carcinoembryonic Antigen: Selection and Characterization.Biology · 2022Article
- Selection and Application of Aptamer Affinity for Protein Purification.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Aptamer based surface plasma resonance assay for direct detection of neuron specific enolase and progastrin-releasing peptide (31-98).RSC advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuron-specific enolase (NSE) is one of the most commonly used serum tumor biomarker in clinical practice for small cell lung cancer screening, early diagnosis, evaluation of therapeutic efficacy and prognosis. In this study, we obtained DNA aptamers with great affinity and selectivity to NSE
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.